Diamyd Medical AB (publ) (DMYD-B) - Cash Flow Conversion Efficiency

Latest as of November 2025: -0.189x

Based on the latest financial reports, Diamyd Medical AB (publ) (DMYD-B) has a cash flow conversion efficiency ratio of -0.189x as of November 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-43.70 Million ≈ $-4.70 Million USD) by net assets (Skr231.63 Million ≈ $24.93 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Diamyd Medical AB (publ) - Cash Flow Conversion Efficiency Trend (2010–2025)

This chart illustrates how Diamyd Medical AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Diamyd Medical AB (publ) debt and liabilities for a breakdown of total debt and financial obligations.

Diamyd Medical AB (publ) Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Diamyd Medical AB (publ) ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
G3 Global Bhd KLSE:7184	-0.010x
Opus One Resources Inc V:OOR	0.000x
Australian Agricultural Projects Ltd AU:AAP	-0.052x
Floyd Public Company Limited BK:FLOYD	0.092x
Reading International B Inc NASDAQ:RDIB	-0.020x
Saudee Group Bhd KLSE:5157	-0.023x
CHARWOOD ENERGY EO -01 F:L5Q	N/A
LogProstyle Inc. NYSE MKT:LGPS	-0.392x

Annual Cash Flow Conversion Efficiency for Diamyd Medical AB (publ) (2010–2025)

The table below shows the annual cash flow conversion efficiency of Diamyd Medical AB (publ) from 2010 to 2025. For the full company profile with market capitalisation and key ratios, see DMYD-B company net worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-08-31	Skr280.00 Million ≈ $30.13 Million	Skr-169.68 Million ≈ $-18.26 Million	-0.606x	+31.55%
2024-08-31	Skr145.92 Million ≈ $15.70 Million	Skr-129.18 Million ≈ $-13.90 Million	-0.885x	-35.15%
2023-08-31	Skr169.40 Million ≈ $18.23 Million	Skr-110.96 Million ≈ $-11.94 Million	-0.655x	-50.64%
2022-08-31	Skr214.38 Million ≈ $23.07 Million	Skr-93.22 Million ≈ $-10.03 Million	-0.435x	+24.82%
2021-08-31	Skr189.26 Million ≈ $20.37 Million	Skr-109.47 Million ≈ $-11.78 Million	-0.578x	-348.38%
2020-08-31	Skr72.49 Million ≈ $7.80 Million	Skr16.88 Million ≈ $1.82 Million	0.233x	+137.31%
2019-08-31	Skr62.78 Million ≈ $6.76 Million	Skr-39.19 Million ≈ $-4.22 Million	-0.624x	+35.41%
2018-08-31	Skr43.01 Million ≈ $4.63 Million	Skr-41.56 Million ≈ $-4.47 Million	-0.966x	-224.51%
2017-08-31	Skr86.67 Million ≈ $9.33 Million	Skr-25.81 Million ≈ $-2.78 Million	-0.298x	+50.91%
2016-08-31	Skr29.26 Million ≈ $3.15 Million	Skr-17.75 Million ≈ $-1.91 Million	-0.607x	-30.94%
2015-08-31	Skr39.52 Million ≈ $4.25 Million	Skr-18.31 Million ≈ $-1.97 Million	-0.463x	-22.60%
2014-08-31	Skr44.16 Million ≈ $4.75 Million	Skr-16.69 Million ≈ $-1.80 Million	-0.378x	-66.13%
2013-08-31	Skr60.29 Million ≈ $6.49 Million	Skr-13.71 Million ≈ $-1.48 Million	-0.227x	-66.41%
2012-08-31	Skr409.58 Million ≈ $44.08 Million	Skr-55.99 Million ≈ $-6.03 Million	-0.137x	+32.98%
2011-08-31	Skr460.97 Million ≈ $49.61 Million	Skr-94.03 Million ≈ $-10.12 Million	-0.204x	-128.44%
2010-08-31	Skr314.78 Million ≈ $33.88 Million	Skr225.77 Million ≈ $24.30 Million	0.717x	--

About Diamyd Medical AB (publ)

ST:DMYD-B Sweden Biotechnology

Market Cap

$15.63 Million

Skr145.25 Million SEK

Market Cap Rank

#25734 Global

#535 in Sweden

Share Price

Skr1.08

Change (1 day)

+2.85%

52-Week Range

Skr1.02 - Skr17.62

All Time High

Skr71.00